Advertisement

Der Nervenarzt

, Volume 89, Issue 2, pp 184–192 | Cite as

Neues zur symptomatischen MS-Therapie: Teil 3 – Blasenfunktionsstörungen

  • T. HenzeEmail author
  • W. Feneberg
  • P. Flachenecker
  • D. Seidel
  • H. Albrecht
  • M. Starck
  • S. G. Meuth
Aktuelles
  • 596 Downloads

Zusammenfassung

Die symptomatische Behandlung der multiplen Sklerose (MS) hat heutzutage neben der Immuntherapie einen hohen Stellenwert im umfassenden Therapiekonzept dieser chronischen Erkrankung, trägt sie doch erheblich zu einer Verringerung von Beeinträchtigungen im Alltag, sozialen und beruflichen Leben sowie zur Verbesserung der Lebensqualität bei. Seit der letzten umfassenden Bestandsaufnahme 2004 in dieser Zeitschrift sowie den Leitlinien der DGN (Deutsche Gesellschaft für Neurologie)/KKN-MS (Klinisches Kompetenznetz Multiple Sklerose) zu Diagnose und Therapie der MS 2014 haben sich Neuerungen und Ergänzungen in den Bereichen Mobilität, Blasenfunktion, Sexualfunktionen, Augen, Fatigue, Kognition und Rehabilitation ergeben. Diese sowie weitere Aspekte (Messmethoden des jeweiligen Symptoms, Therapieziele, Gesamtbehandlungsplan) werden in einer Reihe aus 6 Einzelbeiträgen vorgestellt. Hier soll auf die Symptomatik von Blasenfunktionsstörungen eingegangen werden.

Schlüsselwörter

Multiple Sklerose Symptomatische Therapie Übersichtsartikel Blasenfunktionsstörungen Vegetatives Nervensystem 

What is new in symptomatic MS treatment: Part 3—bladder dysfunction

Abstract

The symptomatic treatment of multiple sclerosis (MS) nowadays is of similar importance as immunotherapy within a comprehensive concept of therapy of this chronic disease, since it contributes considerably to the reduction of disabilities in activities of daily living as well as social and occupational life. Moreover, symptomatic treatment is of great importance for amelioration of quality of life. Since our last survey of symptomatic MS treatment in 2004 and publication of the guidelines of the German Neurological Society and the Klinisches Kompetenznetz Multiple Sklerose (KKNMS) in 2014 several developments within the topics of mobility, bladder and sexual function, vision, fatigue, cognition and rehabilitation took place. These new findings together with further aspects of disease measures and overall treatment strategies of the respective symptoms, as well as treatment goals are introduced in a series of six individual contributions. Here, the symptoms of bladder dysfunction will be discussed.

Keywords

Multiple sclerosis Symptomatic treatment Review Bladder dysfunction Vegetative nervous system 

Notes

Danksagung

Wir bedanken uns bei der Firma Almirall Hermal für finanzielle Hilfe bei der technischen Erstellung des Manuskripts, ebenso bei Frau Dr. U. Essner sowie Frau Dr. P. Hundehege und Frau L. Forster (Neurologische Universitätsklinik Münster) für ihre Hilfe bei der Erstellung des Manuskripts.

Einhaltung ethischer Richtlinien

Interessenkonflikt

T. Henze erhielt Vortragshonorare und Aufwandsentschädigungen für Advisory Boards von Almirall, Coloplast, Genzyme, Novartis, Sanofi. Interessenkonflikte bestehen nicht. W. Feneberg erhielt Vortragshonorare, Aufwandsentschädigungen für Advisory Boards bzw. Unterstützung bei Fortbildungen von Almirall, Bayer, Biogen Idec, Coloplast, Genzyme, Ipsen, Merz, Novartis, Sanofi-Aventis. Interessenkonflikte bestehen nicht. P. Flachenecker hat Honorare für Vorträge und Beratungstätigkeiten von den Firmen Almirall, Bayer, Biogen Idec, Genzyme, Novartis, Merck Serono, Roche und Teva erhalten und an industriegesponsorten Studien von Biogen Idec und Novartis teilgenommen. Interessenkonflikte bestehen nicht. H. Albrecht hat Zahlungen für Reisekosten und/oder Fortbildungsveranstaltungen und/oder Studien erhalten von Almirall, Bayer Healthcare, Biogen Idec, Genzyme-Sanofi, Merck Serono, Teva. S.G. Meuth erhielt Vortragshonorare, Aufwandsentschädigungen für Advisory Boards bzw. Unterstützung bei Fortbildungen und/oder Projektförderung von Bayer, Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi-Aventis und Teva. D. Seidel und M. Starck geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Amarenco G, Chartier-Kastler E, Denys P et al (2013) First-line urological evaluation in multiple sclerosis: validation of a specific decision-making algorithm. Mult Scler 19:1931–1937CrossRefPubMedGoogle Scholar
  2. 2.
    Amarenco G, de Seze M, Ruffion A et al (2014) Clinical and urodynamic evaluations of urinary disorders in multiple sclerosis. Ann Phys Rehabil Med 57:277–287CrossRefPubMedGoogle Scholar
  3. 3.
    Pannek J, Mark R, Stöhrer M et al (2007) Quality of life in German-speaking patients with spinal cord injuries and bladder dysfunctions. Validation of the German version of the Qualiveen questionnaire. Urologe A 46:1416–1421CrossRefPubMedGoogle Scholar
  4. 4.
    Wallace SA, Roe B, Williams K et al (2004) Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD001308.pub2 Google Scholar
  5. 5.
    Henze T, Rieckmann P, Toyka KV (2004) Symptomatische Therapie der Multiplen Sklerose. Nervenarzt 75(Suppl 1):2–39PubMedGoogle Scholar
  6. 6.
    Wang AC, Wang YY, Chen MC (2004) Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. Urology 63:61–66CrossRefPubMedGoogle Scholar
  7. 7.
    McClurg D, Ashe RG, Lowe-Strong AS (2008) Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis — a double blind, placebo controlled, randomised clinical trial. Neurourol Urodyn 27:231–237CrossRefPubMedGoogle Scholar
  8. 8.
    de Seze M, Raibaut P, Gallien P et al (2011) Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn 30:306–311CrossRefPubMedGoogle Scholar
  9. 9.
    Gobbi C, Digesu GA, Khullar V et al (2011) Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial. Mult Scler 17:1514–1519CrossRefPubMedGoogle Scholar
  10. 10.
    Lucio AC, D’Ancona CA, Lopes MH et al (2014) The effect of pelvic floor muscle training alone or in combination with electrostimulation in the treatment of sexual dysfunction in women with multiple sclerosis. Mult Scler 20:1761–1768CrossRefPubMedGoogle Scholar
  11. 11.
    Khan F, Pallant JF, Pallant JI et al (2010) A randomised controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis. J Neurol Neurosurg Psychiatry 81:1033–1038CrossRefPubMedGoogle Scholar
  12. 12.
    Lucio A, D’Ancona CA, Perissinotto MC et al (2016) Pelvic floor muscle training with and without electrical stimulation in the treatment of lower urinary tract symptoms in women with multiple sclerosis. J Wound Ostomy Continence Nurs 43:414–419CrossRefPubMedGoogle Scholar
  13. 13.
    Ferreira AP, Pegorare AB, Salgado PR et al (2016) Impact of a pelvic floor training program among women with multiple sclerosis: a controlled clinical trial. Am J Phys Med Rehabil 95:1–8CrossRefPubMedGoogle Scholar
  14. 14.
    Madhuvrata P, Singh M, Hasafa Z et al (2012) Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol 62:816–830CrossRefPubMedGoogle Scholar
  15. 15.
    Nicholas RS, Friede T, Hollis S et al (2009) Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD004193 PubMedGoogle Scholar
  16. 16.
    Phe V, Chartier-Kastler E, Panicker JN (2016) Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol 13:275–288CrossRefPubMedGoogle Scholar
  17. 17.
    Ethans KD, Nance PW, Bard RJ et al (2004) Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 27:214–218CrossRefPubMedGoogle Scholar
  18. 18.
    Panicker JN, Fowler CJ, Kessler TM (2015) Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol 14:720–732CrossRefPubMedGoogle Scholar
  19. 19.
    Amend B, Hennenlotter J, Schäfer T et al (2008) Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 53:1021–1028CrossRefPubMedGoogle Scholar
  20. 20.
    Bosma R, Wynia K, Havlikova E et al (2005) Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand 112:1–5CrossRefPubMedGoogle Scholar
  21. 21.
    Freeman RM, Adekanmi O, Waterfield MR et al (2006) The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J 17:636–641CrossRefGoogle Scholar
  22. 22.
    Brady CM, DasGupta R, Dalton C et al (2004) An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10:425–433CrossRefPubMedGoogle Scholar
  23. 23.
    Kavia RB, De Ridder D, Constantinescu CS et al (2010) Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 16:1349–1359CrossRefPubMedGoogle Scholar
  24. 24.
    Solaro C, Bergamaschi R, Rezzani C et al (2013) Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study. Clin Neuropharmacol 36:114–116CrossRefPubMedGoogle Scholar
  25. 25.
    Di Rezze S, Frasca V, Inghilleri M et al (2012) Duloxetine for the treatment of overactive bladder syndrome in multiple sclerosis: a pilot study. Clin Neuropharmacol 35:231–234CrossRefPubMedGoogle Scholar
  26. 26.
    Cameron AP, Clemens JQ, Latini JM et al (2009) Combination drug therapy improves compliance of the neurogenic bladder. J Urol 182:1062–1067CrossRefPubMedGoogle Scholar
  27. 27.
    Drutz HP, Appell RA, Gleason D et al (1999) Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J 10:283–289CrossRefGoogle Scholar
  28. 28.
    Jacquetin B, Wyndaele J (2001) Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol 98:97–102CrossRefPubMedGoogle Scholar
  29. 29.
    Cardozo L, Chapple CR, Toozs-Hobson P et al (2000) Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 85:659–664CrossRefPubMedGoogle Scholar
  30. 30.
    Stöhrer M, Madersbacher H, Richter R et al (1999) Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia — a double-blind, placebo-controlled clinical trial. Spinal Cord 37:196–200CrossRefPubMedGoogle Scholar
  31. 31.
    Ginsberg D, Cruz F, Herschorn S et al (2013) OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther 30:819–833CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Hess MJ, Hess PE, Sullivan MR et al (2008) Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder. Spinal Cord 46:622–626CrossRefPubMedGoogle Scholar
  33. 33.
    Guay DR (2009) Cranberry and urinary tract infections. Drugs 69:775–807CrossRefPubMedGoogle Scholar
  34. 34.
    Wang CH, Fang CC, Chen NC et al (2012) Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 172:988–996PubMedGoogle Scholar
  35. 35.
    Gallien P, Amarenco G, Benoit N et al (2014) Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: a multicenter, randomized, placebo-controlled, double-blind trial. Mult Scler 20:1252–1259CrossRefPubMedGoogle Scholar
  36. 36.
    Kranjcec B, Papes D, Altarac S (2014) D‑mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol 32:79–84CrossRefPubMedGoogle Scholar
  37. 37.
    Blok B, Pannek J, Castro Diaz D, European Association of Urology, - (2015) Guidelines on neuro-urology. https://uroweb.org/wp-content/uploads/EAU-Guidelines-Neuro-Urology-2015-v2.pdf. Zugegriffen: 30.5.2016Google Scholar
  38. 38.
    Seth JH, Haslam C, Panicker JN (2014) Ensuring patient adherence to clean intermittent self-catheterization. Patient Prefer Adherence 8:191–198PubMedPubMedCentralGoogle Scholar
  39. 39.
    Böthig R, Geng V, Kurze I, DMGP (2014) Management und Durchführung des Intermittierenden Katheterismus (IK) bei Neurogenen Blasenfunktionsstörungen. http://www.awmf.org/uploads/tx_szleitlinien/043-048l_S2k_Management_IK_Neurogene_Blasenfunktionsstörungen_2016-10.pdf. Zugegriffen: 30.5.2016Google Scholar
  40. 40.
    Vahter L, Zopp I, Kreegipuu M et al (2009) Clean intermittent self-catheterization in persons with multiple sclerosis: the influence of cognitive dysfunction. Mult Scler 15:379–384CrossRefPubMedGoogle Scholar
  41. 41.
    Weckx F, Tutolo M, De Ridder D et al (2016) The role of botulinum toxin A in treating neurogenic bladder. Transl Androl Urol 5:63–71PubMedPubMedCentralGoogle Scholar
  42. 42.
    Cruz F, Herschorn S, Aliotta P et al (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60:742–750CrossRefPubMedGoogle Scholar
  43. 43.
    Ginsberg D, Gousse A, Keppenne V et al (2012) Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 187:2131–2139CrossRefPubMedGoogle Scholar
  44. 44.
    Schurch B, Denys P, Kozma CM et al (2007) Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 52:850–858CrossRefPubMedGoogle Scholar
  45. 45.
    Karsenty G, Denys P, Amarenco G et al (2008) Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 53:275–287CrossRefPubMedGoogle Scholar
  46. 46.
    Mangera A, Andersson KE, Apostolidis A et al (2011) Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 60:784–795CrossRefPubMedGoogle Scholar
  47. 47.
    Deffontaines-Rufin S, Weil M, Verollet D et al (2011) Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Int Braz J Urol 37:642–648CrossRefPubMedGoogle Scholar
  48. 48.
    Buyse G, Waldeck K, Verpoorten C et al (1998) Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 160:892–896CrossRefPubMedGoogle Scholar
  49. 49.
    Krause P, Fuhr U, Schnitker J et al (2013) Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. J Urol 190:1791–1797CrossRefPubMedGoogle Scholar
  50. 50.
    Humblet M, Verpoorten C, Christiaens MH et al (2015) Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. Neurourol Urodyn 34:336–342CrossRefPubMedGoogle Scholar
  51. 51.
    de Seze M, Ruffion A, Denys P et al (2007) The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 13:915–928CrossRefPubMedGoogle Scholar
  52. 52.
    Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M et al (2000) Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 164:1476–1480CrossRefPubMedGoogle Scholar
  53. 53.
    Marinkovic SP, Gillen LM (2010) Sacral neuromodulation for multiple sclerosis patients with urinary retention and clean intermittent catheterization. Int Urogynecol J 21:223–228CrossRefPubMedGoogle Scholar
  54. 54.
    Minardi D, Muzzonigro G (2012) Sacral neuromodulation in patients with multiple sclerosis. World J Urol 30:123–128CrossRefPubMedGoogle Scholar
  55. 55.
    Puccini F, Bhide A, Elneil S et al (2016) Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis. Int Urogynecol J 27:347–354CrossRefPubMedGoogle Scholar
  56. 56.
    Engeler DS, Meyer D, Abt D et al (2015) Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series. BMC. Urology 15:105PubMedPubMedCentralGoogle Scholar
  57. 57.
    Legrand G, Roupret M, Comperat E et al (2011) Functional outcomes after management of end-stage neurological bladder dysfunction with ileal conduit in a multiple sclerosis population: a monocentric experience. Urology 78:937–941CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH 2017

Authors and Affiliations

  • T. Henze
    • 1
    Email author
  • W. Feneberg
    • 3
  • P. Flachenecker
    • 4
  • D. Seidel
    • 5
  • H. Albrecht
    • 6
  • M. Starck
    • 3
  • S. G. Meuth
    • 2
  1. 1.Praxisgemeinschaft für Neurologie, Psychiatrie, PsychotherapieRegensburgDeutschland
  2. 2.Department für Neurologie und Institut für Translationale NeurologieKlinik für Allgemeine Neurologie, UniversitätsklinikumMünsterDeutschland
  3. 3.Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gemeinnützige GmbHBergDeutschland
  4. 4.Neurologisches Rehabilitationszentrum QuellenhofBad WildbadDeutschland
  5. 5.BocholtDeutschland
  6. 6.Praxis für NeurologieMünchenDeutschland

Personalised recommendations